A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Cutaneous Squamous Cell Carcinoma · SCC - Squamous Cell Carcinoma · Basal Cell Carcinoma · BCC · BCC - Basal Cell Carcinoma · Melanoma · Merkel Cell Carcinoma · Sebaceous Carcinoma · Extramammary Paget Disease · Kaposi Sarcoma · Head and Neck Squamous Cell Carcinoma · HNSCC · Adnexal Carcinoma · Angiosarcoma · Cutaneous Neoplasm · Advanced Cancer · Metastatic Cancer · Refractory Cancer · Solid Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States

    Contact: Study coordinator (Lara Dunn, MD) · 646-608-3787
  • Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown, New Jersey, United States

    Contact: Study coordinator (Lara Dunn, MD) · 646-608-3787
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States

    Contact: Study coordinator (Lara Dunn, MD) · 646-608-3787
  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States

    Contact: Study coordinator (Lara Dunn, MD) · 646-608-3787
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States

    Contact: Study coordinator (Lara Dunn, MD) · 646-608-3787
Study leads
  • Lara Dunn, MD

    Principal Investigator

    Memorial Sloan Kettering Cancer Center